VRTX · 10-Q · 2026Q3 · Full report
Povetacicept Regulatory Review
VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 47 · Surprise 60 · In source text
The FDA placed Vertex’s biologics license application for accelerated approval of povetacicept in adults with IgA nephropathy (IgAN) under priority review, with a target action date of November 30, 2026. If approved, Vertex says the medicine would be the first commercialized therapy in its emerging nephrology franchise. Povetacicept is also under accelerated-approval review for adults with IgAN in Saudi Arabia, where the Saudi Food and Drug Authority granted Breakthrough designation.
Key facts
- The FDA is conducting priority review of the povetacicept BLA for accelerated approval in adults with IgAN, with a PDUFA target action date of November 30, 2026. source
- Povetacicept is under review for accelerated approval for adults with IgAN in Saudi Arabia, and the Saudi Food and Drug Authority granted it Breakthrough designation. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | The FDA is conducting priority review of the povetacicept BLA for accelerated approval in adults with IgAN, with a PDUFA target action… |
| revenue | positive | contingent | — | Povetacicept is under review for accelerated approval for adults with IgAN in Saudi Arabia, and the Saudi Food and Drug Authority granted… |